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Introduction: Tuberculosis (TB) is an important cause of morbidity and mortality in HIV patients. It 
is unknown if the advent of molecular diagnostic methods and a greater availability of antiretroviral 
therapy (ART) in our country have changed some characteristics of the TB/HIV co-infection.
Objective: To describe the epidemiology, clinical features, diagnosis, resistance patterns, tuberculosis 
drug effects and mortality in co-infected patients.
Materials and methods: Retrospective study based on the review of medical records of hospitalized 
co-infected adults in a university hospital in Medellín, Colombia.
Results: A total of 178 patients was included in the study. TB and HIV diagnosis was simultaneous in 
49.4%. In the moment of TB diagnosis, the median CD4 count was 61 cells/µL (27-145). Pulmonary 
tuberculosis (PTB) occurred in 28% of patients, extrapulmonary (EPTB) in 23%, and mixed TB in 48.9%. 
The main EPTB affectations were lymphatic (55.4%), gastrointestinal (35.9%), and of the central nervous 
system (18.7%). Ziehl-Neelsen stain was positive in 137 patients (77%), mycobacterium culture in 121 
(68%), and TB-PCR, in 85 of those patients in whom the test was done. Rifampicin resistance was 
detected in six cases (4.9%). Transaminases (ALT) increased in half of the patients during TB treatment, 
but only 10% met liver-toxicity criteria. In-hospital mortality was 11.3%. The single risk factor associated 
with mortality was CD4 count <50/µL (RR=3.9; 95% CI: 1.36-11.37; p=0.01).
Conclusions: When it occurs as an opportunistic infection, TB usually leads to the diagnosis of advanced 
HIV disease. If used appropriately, TB diagnosis in these patients can be done by conventional methods. 
It is always necessary to monitor liver function during TB treatment and to rule out drug resistance.
Key words: Tuberculosis; HIV; acquired immunodeficiency syndrome; drug-related side effects and 
adverse reactions; drug resistance; molecular diagnostic techniques.
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Características actuales de la coinfección con tuberculosis y el virus de la inmunodeficiencia 
humana en pacientes hospitalizados en Medellín, Colombia
Introducción. La tuberculosis es una causa importante de morbilidad y mortalidad en pacientes 
positivos para el HIV. Los métodos de diagnóstico molecular y una mayor disponibilidad del tratamiento 
antirretroviral en el país pueden haber cambiado las características de la infección concomitante.
Objetivo. Describir la epidemiología, las características clínicas, el diagnóstico, los patrones de 
resistencia, los efectos secundarios de los medicamentos antituberculosos y la mortalidad, en pacientes 
con las dos infecciones.
Materiales y métodos. Se hizo un estudio retrospectivo basado en la revisión de historias clínicas de 
adultos hospitalizados en un hospital universitario de Medellín, Colombia. 
Resultados. Se incluyeron 178 pacientes en el estudio. El diagnóstico de tuberculosis e infección por 
el HIV fue simultáneo en 49,9 %. En el momento del diagnóstico, la mediana de CD4 fue de 61 células/
µL (rango de 27 a 145). La tuberculosis pulmonar ocurrió en 28 % de los pacientes, la extrapulmonar 
en 23% y la mixta en 48,9%. En la tuberculosis extrapulmonar, el compromiso fue principalmente 
linfático (55,4 %), gastrointestinal (35,9%) y del sistema nervioso central (18,7 %). La tinción de Ziehl-
Neelsen fue positiva en 137 pacientes (77 %), en tanto que el cultivo para micobacterias lo fue en 
121 (68 %). La reacción en cadena de la polimerasa para detectar la tuberculosis fue positiva en 85 
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de los pacientes a quienes se les hizo la prueba. Se detectó resistencia a la rifampicina en seis casos 
(4,9 %). Al iniciar el tratamiento antituberculoso, las transaminasas se elevaron en la mitad de los 
pacientes, pero solo 10 % cumplieron los criterios de hepatotoxicidad. La mortalidad hospitalaria fue 
de 11,3 %. El único factor de riesgo asociado con la mortalidad fue un conteo de CD4 menor de 50/
µL (RR=3,9; IC95% 1,36-11,37; p=0,01).
Conclusiones. Cuando la tuberculosis se presenta de manera oportunista, comúnmente lleva al 
diagnóstico de enfermedad avanzada por el HIV. Su diagnóstico en estos pacientes puede hacerse 
con los métodos convencionales. Es necesario vigilar la función hepática durante el tratamiento y 
excluir la resistencia a los medicamentos.
Palabras clave: tuberculosis; VIH; síndrome de inmunodeficiencia adquirida; efectos colaterales y 
reacciones adversas relacionados con medicamentos; resistencia a medicamentos; técnicas de 
diagnóstico molecular.
doi: https://doi.org/10.7705/biomedica.v38i3.3862
Tuberculosis (TB) continues to be an important 
cause of morbidity and mortality in individuals that 
are positive for the human immunodeficiency virus 
(HIV). Worldwide, 11.2% of the 10.4 million new TB 
cases in 2015 occurred in HIV-infected individuals. 
HIV co-infection is an important risk factor for the 
acquisition and development of active TB (1). 
Tuberculosis was reported to cause 1.4 million of 
deaths in 2015, 0.4 million of them among HIV-
positive patients. In 2015, 268,000 active TB cases 
were reported in the Americas, 12% were co-
infections with HIV, and 19% of patients died due 
to the co-infection. In that same year, 15,000 active 
TB cases were reported in Colombia, of which 14% 
were co-infections with HIV, similar to the 16% 
reported in 1995 in our institution (Velásquez G, 
García H, Arboleda C, Castro J, Díaz S, Garcés MC, 
et al. Características de la enfermedad tuberculosa 
y cumplimiento con las normas de aislamiento en 
un hospital universitario entre 1995 y 1998. Resu-
men A3. II Encuentro Nacional de Investigación en 
Enfermedades Infecciosas. Infectio. 2000;4:17).
Many co-infected patients are diagnosed only 
when they reach a third-level center; therefore, the 
diagnosis is late and leads to prolonged hospitali-
zations. Exploring risk factors for late diagnosis in 
191 co-infected patients, Rossato, et al. (2) found 
that extrapulmonary TB and smear-negative TB 
contributed significantly to this delay.
HIV coinfection increases the risk of tuberculosis 
drug-induced liver injury (DILI) (3), complicating 
management and frequently forcing the discontinua-
tion of first-line therapy and the use of alternative 
medications. On the other hand, TB/HIV co-infection 
also increases the risk of drug-resistant tuberculosis 
(4). These diagnostic and management challenges, 
adverse effects, and drug interactions all contribute 
to increase hospitalization rates and duration, as 
well as the cost of the therapy, with associated 
worse outcomes.
Recently, the advent of new molecular diagnostic 
tests for TB and a greater availability of antiretro-
viral therapy (ART) in Colombia may have changed 
the characteristics of TB/HIV co-infection in our 
patients. This study aimed to evaluate the current 
features of the co-infection, tuberculosis drug 
effects starting therapy, the impact of TB resistance 
and mortality in a cohort of TB/HIV co-infected 
patients hospitalized in a high-complexity hospital 
in Medellín, Colombia.
Materials and methods
Study design and population
We conducted a retrospective clinical chart review 
of hospitalized patients with TB/HIV co-infection in 
the Hospital Universitario San Vicente Fundación, 
(HUSVF) (a reference healthcare center for these 
kind of patients) in Medellín, Colombia, between 
2007 and 2015, and of registers from Antioquia’s 
health information systems (Dirección Seccional 
de Salud de Antioquia, DSSA). 
Inclusion criteria were age 15 years or older with a 
confirmed diagnosis of HIV and active TB infection, 
and complete access to the medical record of 
everyone. Patients were excluded in the absence 
of confirmed HIV or TB infection when charts were 
not available, or when any other mycobacteria 
different from Mycobacterium tuberculosis grew in 
the culture. All patients were under the medical care 
of the infectious diseases section of the Hospital.
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Data collection and definitions 
We collected all the demographic and epidemio-
logical variables, as well as clinical, laboratory and 
treatment information regarding the co-infection. 
The confirmation of HIV infection required a 
positive Western blot or HIV viral load. In patients 
with a compatible clinical picture and no alternative 
diagnosis to explain it, TB was defined by the 
positivity of at least one of the following: i) Ziehl-
Neelsen (ZN) stained smear; ii) M. tuberculosis 
culture; iii) ZN positive in compatible histopathology, 
and iv) M. tuberculosis molecular tests according 
to the diagnostic criteria of the World Health 
Organization (5). We used Ziehl-Neelsen stain 
for the entire duration of the study. Regarding the 
media for mycobacterial cultures, Ogawa was 
used between 2007 and 2012, Lowenstein from 
2012 to 2015 and MGIT liquid culture as of 2015. 
Molecular tests have been performed since 2011 in 
the Hospital. Lymphocytes CD4+ count, HIV viral 
load, hepatitis B and C, and syphilis serology were 
obtained during the same hospitalization period in 
which co-infection was diagnosed.
Anemia was defined as a hemoglobin level of 
less than 13 g/dl in men and less than 12 g/dl in 
women; leukopenia as cell counts less than 4,000/
µL, and thrombocytopenia as platelet count less 
than 100,000/µL. Clinical instability at admission 
was defined as a patient with at least three of the 
following vital signs out of normal range: Heart 
rate, 60-100/minute; spontaneous respiratory rate, 
12-22/minute; systolic blood pressure, 90-120 mm 
Hg; temperature, 36.5-38.2°C, and pulse oximetry 
≥90% without supplementary oxygen.
The TB clinical presentation was classified as 
pulmonary, extrapulmonary or mixed according 
to the compromised organs. TB treatment was 
categorized in two groups: i) First-line scheme 
[isoniazid (H), rifampicin (R), pyrazinamide (Z) 
and ethambutol (E)], and ii) a modified scheme 
when due to the clinical condition, adverse events, 
comorbidities, drug interactions or resistance to 
any TB medication, treatment included medications 
different from the first-line scheme. 
Hepatotoxicity was defined as serum values of 
alanine aminotransferase (ALT)  five times above 
the upper limit of normal (ULN) values in asymp-
tomatic patients, or more than three times in 
patients with jaundice or gastrointestinal symptoms 
(6). Due to the retrospective character of the 
study, other clinical complications and adverse 
events associated with TB medications were only 
considered if they were verified by the specialist in 
infectious diseases in charge and documented in 
the clinical chart. 
Poor adherence to treatment was defined as 
partial or total interruptions of treatment for more 
than a week prior to hospitalization, either by 
the patient’s own decision or due to difficulties in 
accessing health services. Due to the nature of 
the chart review, we were not able to differentiate 
between them.
Positive cultures for mycobacteria were sent to 
Antioquia’s laboratory of public health (Laboratorio 
de Salud Pública) for first-line drugs susceptibility 
testing. There, the susceptibility to rifampicin was 
confirmed by molecular methods and to all the 
first-line drugs by the proportions method. If MDR 
was found, these resistant strains were sent to the 
laboratory of the Instituto Nacional de Salud  for 
evaluating the susceptibility to second-line drugs.
Statistical analysis
After we screened the database of all HIV patients 
for co-infection with TB, we did descriptive statistics 
of collected data. All variables were expressed 
as percentage or median and interquartile range 
(IQR). We evaluated risk factors associated with 
mortality using a binomial regression analysis 
adjusted by age. Covariates included in the analysis 
were previous ART, homelessness, previous TB, 
hepatitis B infection, main organs affected by TB, 
CD4 count cells <50/mm3, HIV viral load ≥100,000, 
reactive VDRL, and hepatotoxicity. Results were 
expressed as adjusted relative risk with their 95% 
confidence interval. Data were analyzed in the 
statistic program SPSS™, version 22, and Stata™, 
version 12.0.
Ethics statement
The ethical committees of the Universidad de 
Antioquia and the HUSVF approved the study.
Results
We screened 221 hospitalized patients with sus-
pected TB/HIV co-infection within the 2007-2015 
period of whom 178 were included and 43 excluded. 
The main baseline features of these patients are 
shown in table 1. 
TB and HIV diagnosis were confirmed simultane-
ously in 49.4% patients (86/174); of the remaining 
individuals with previous HIV diagnosis, only 38 
had been on ART, the majority of them with poor 
adherence and advanced immunosuppression. 
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Other co-infections diagnosed during hospitali-
zation were toxoplasmosis in 10% of patients, 
histoplasmosis in 5.6%, cryptococcosis in 4.5%, 
and pneumocystosis in 3.4%. More than half 
(56.6%) of the patients had prior history of syphilis, 
33% had been naturally exposed to wild hepatitis 
B virus (reactive AbHBc IgG), 8.9% were chronic 
carriers of AgsHB, and 19% had developed pro-
tective titers of AbHBs (>10 mIU/mL); 2.6% had 
evidence of previous exposition to hepatitis C 
(positive anti-HCV) (table 1).
At admission, 15% of patients had evidence of 
clinical instability, 86% anemia, 20% leucopenia, 
23.5% thrombocytopenia, and 111 of 177 (63%) 
had liver function tests within normal range.
Clinical characteristics of TB in HIV-positive 
patients
Table 2 shows the clinical features at admission. 
Around 28% (50) of patients had pulmonary TB 
(PTB), 23% (41) extrapulmonary TB (EPTB) and 
49% (87) disseminated disease. The organs and 
systems commonly affected in EPTB were lympha-
tic nodes (55.4%), peritoneum or gastrointestinal 
tract (35.9%), central nervous system (18.7%), 
and pleura (9.3%). Other TB presentations were 
genito-urinary (6 cases), bone marrow (6 cases), 
osteoarticular (3 cases), muscular (3 cases), 
pericardial (2 cases), laryngotracheal (1 case), 
ophthalmic (1 case), dorso-lumbar myelitis (1 case), 
mastoiditis (1 case), and cutaneous (1 case).
Microbiological diagnosis of TB 
Table 3 shows the laboratory tool used for the 
diagnosis of TB. In general, Ziehl-Neelsen (ZN) 
stain was positive in 137 patients (77%), culture 
in 121 (68%), and M. tuberculosis PCR in 85 of 
the patients in whom this test was done. However, 
PCR supported the TB diagnosis in 25 patients 
with negative ZN. In 29 (16.3%) of the 178 patients 
the diagnosis was made only with ZN, and three 
of them died during the follow-up. In the two cases 
with negative ZN, culture and PCR, TB diagnosis 
was based on histopathology with positive ZN in 
tissues, clinical picture compatible with TB, and 
absence of an alternative diagnosis.
Drug-susceptibility testing
Among all first-line antibiotics tested, resistance 
to rifampicin was detected in six of 123 cases with 
available information (4.9%): Four had multidrug-
resistant tuberculosis (MDR-TB), one had pre-
extensively drug resistance (pre-XDR), resistance 
to INH, SM, RMP, and EMB (HRSE), ethionamide 
and levofloxacin, and no susceptibility test to 
pyrazinamide available (this patient had prior 
history of treated gastrointestinal TB and drug 
Table 1. Baseline characteristics of 178 hospitalized patients with 
TB/HIV co-infection in a university hospital in Medellín, Colombia 
General characteristics 
Age, years, median (IQR) 38 (29-45)
Male sex, n (%) 137/178 (77) 
HIV status
Known HIV diagnosis at admission, n (%) 88/174 (50,6) 
HIV viral load (copies/µl), 
median (IQR) 
191,000 
(42,300-750,000) 
Lymphocytes T CD4+ count 
(cells/mL), median (IQR)
61 (27-145) 
CD4 >200 cells/mL, n (%) 28/176 (16)
CD4 50-200 cells/mL, n (%) 74/176 (42) 
CD4 <50 cells/mL, n (%) 74/176 (42) 
Past medical history, n (%)
Previous TB episode 37/176 (21)
Previous exposition to hepatitis B virus 47/141 (33.3)
Previous exposition to hepatitis C virus 4/152 (2.6) 
Alcoholism 6/178 (3.4) 
Chronic kidney disease 5/178 (2.8)
Epidemiological conditions, n (%)
Homeless 26/177 (14.7)
Previous contact with a TB patient 13/123 (10.6) 
Prisoners 6/176 (3.4) 
Intravenous drugs users 4/175 (2.3) 
Table 2. Clinical characteristics of TB in 178 HIV-positive patients
Characteristics n (%)
Symptoms
Fever 154/178 (86.5) 
Cough 136/178 (76.4) 
Weight loss 132/178 (74.2) 
Diarrhea   99/178 (55.6) 
Night sweats   87/178 (48.9)
Dyspnea   63/178 (35.4)
Headache   62/178 (34.8)
Stomachache 57/178 (32)
Altered mental status   26/177 (14.7) 
Chest pain   23/178 (12.9) 
Signs                                                                    
Lymphadenopathy 105/177 (59.3)
Hepatomegaly   43/178 (24.2)
Splenomegaly   26/178 (14.6)
Ascites     6/178   (3.4) 
Abdominal mass     4/177   (2.3) 
TB presentation                                                    
Pulmonary, exclusively   50/178 (28.1)
Extrapulmonary, exclusively   41/178 (23.0) 
Mixed presentation   87/178 (48.9) 
Radiographic patterns                                         
Hilar or paratracheal lymphadenopathies   68/173 (39.3)
Miliary pattern   40/172 (23.3)
Cavitations   20/173 (11.6) 
Other findings compatibles with TB* 111/173 (64.2) 
*Anyone with the following radiological findings: Pleural effusion, budding 
tree pattern, consolidation, or interstitial opacities
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addiction disorder). The sixth case had resistance 
to rifampicin by a genotyping test (Gene Xpert™ 
MTB/RIF), but no susceptibility testing to other 
anti-tuberculous drugs was done.
Adverse events associated with anti-TB drugs
TB therapy was started in the hospital in 169 
patients, 159 with the first-line scheme (HRZE), 
three with HZE plus moxifloxacin, one with RZE 
plus moxifloxacin, one with HRZ plus levofloxacin, 
two with HZE plus rifabutin, and three with second-
line medications. Five did not receive in-hospital TB 
therapy because acid-fast stains had been negative 
and they were discharged before culture results 
were available, two died before the treatment could 
be initiated, and for two of the patients we had no 
available information. 
An ALT increase was the most frequent adverse 
event associated with anti-TB therapy. ALT was 
measured in 177 patients and more than once in 
152 (median=4.0, IQR: 2.0-6.0). Before starting 
TB treatment, the median of ALT was 26 U/L (IQR: 
18-48). ALT was followed up for 18 days (IQR: 12-
29) and 12 days was the time to get the maximal 
ALT value (IQR: 8-17). Among the 152 patients 
with more than one value available, 98 started TB 
treatment with normal ALT (64%), and 76 (50%) had 
an increase during the treatment; in eight the ULN 
increased between 3 and 5 times, in seven, more 
than 5 times, while none of the other 54 patients 
(36%) who started with an ALT level higher than the 
ULN increased more than twice the basal value.
Of the 159 patients who started on HRZE, 134 (84%) 
continued on the same medications at discharge, 
but 25 (16%) were switched to a modified scheme. 
Hepatotoxicity, according to the established defini-
tion, was present in 15 cases (10%); three of them 
restarted the same medications once normal values 
were reached, and 12 begun a modified treatment. 
In addition to liver toxicity, in 13 patients there 
were other reasons to change TB treatment: Nine 
cases due to drug interactions, two cases because 
of in-hospital detection of drug-resistant TB, and 
one case because of bone marrow toxicity and 
another discontinuation attributed to arthralgias. 
Other reported side effects that did not require 
interruption or changes on anti-TB treatment were 
bone marrow toxicity in 6%, skin allergy in 3%, and 
neurotoxicity and nephrotoxicity in three and two 
cases, respectively. The immune reconstitution 
inflammatory syndrome (IRIS) was detected in 4% 
of the patients.
Risk factors associated with mortality 
The median hospital stay was 19 days (IQR: 13-
28), and the in-hospital mortality was 11.3% (20 
of 177). According to registers of the local health 
information systems, at the end of February of 
2015, 61 of the patients included in this study had 
died (34.3%). By multivariate analysis, having 
a CD4 count below 50 cells/mL was the only 
risk factor associated with in-hospital mortality 
(RR=3.94, 95% CI 1.36-11.37) (table 4).
Discussion
Our results highlight the fact that TB, a common 
opportunistic infection, led to the diagnosis of 
advanced HIV disease in about half of co-infected 
patients included in the study. Most of them were 
very immunocompromised and presented with 
disseminated and extrapulmonary disease, and 
almost 5% were resistant to rifampicin (generally 
associated with other resistances). During hospital 
stay, 16% had to interrupt or modify the TB first-line 
drugs (10% by hepatotoxicity), and CD4 cells<50/
µL at admission was the single factor associated 
with in-hospital mortality.
Despite of the knowledge amassed about HIV 
infection, the progress in ART and a better access 
of patients to it worldwide, as well as the availability 
of rapid diagnostic and drug-susceptibility tests for 
TB in the last years, our results show that even in 
countries with moderate TB incidence like Colom-
bia, TB is still frequently diagnosed among patients 
with advanced HIV-associated immunosuppres-
sion (Velásquez G, Mejía P, Restrepo N, Betancour 
J. Comportamiento de la tuberculosis en paciente 
infectados por el virus de la inmunodeficiencia 
Table 3. Percentage of HIV/TB co-infected patients whose 
microbiological TB diagnosis was obtained by one or more 
diagnostic methods
Microbiological method n %
ZN+, culture+, PCR+ 45 25,3
ZN+, culture+, PCR- 48 27,0
ZN+, culture-, PCR+ 15   8,4
ZN+, culture-, PCR- 29 16,3
ZN-, culture+, PCR- 14   7,9
ZN-, culture-, PCR+ 11   6,2
ZN-, culture+, PCR+ 12   6,7
Culture +, PCR+ (*)   2   1,1
ZN-, culture-, PCR- (**)   2   1,1
ZN: Ziehl-Neelsen stain; culture: Mycobacterium culture; PCR: Polymerase 
chain reaction
* No ZN available for two patients
** In two of the patients, diagnosis was made by compatible histopathology 
with positive ZN in tissues
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humana. Resúmenes del Segundo Encuentro 
Nacional de Investigación en Enfermedades 
Infecciosas. Medellín, Sociedad Colombiana de 
Infectología, 2000:4(1) Abs. E3:32.) (7-14). 
Some possible reasons include late access to 
health systems (our hospital serves a community 
with low resources and poor access to health 
services) and structural delays in access to diag-
nosis and care. Barriers for antiretroviral therapy 
initiation are present despite global access to free 
antiretrovirals, which partially explains the fact 
that only 38 of the previously diagnosed indivi-
duals were on ART. The lack of early access to 
ART, even in the face of opportunistic infection, 
leads to repeated admissions, high costs, and 
poor outcomes. Individual characteristics such as 
alcohol and drug addiction, poor awareness of risk 
behaviors, misinformation regarding HIV disease 
(both among doctors and patients), and the fear of 
HIV test contribute as well to this situation. The fact 
that more than half of our patients are young adults 
previously exposed to other sexually transmitted 
diseases as syphilis and hepatitis B suggests poor 
knowledge about preventive measures and no 
awareness about risk behaviors, as well as limited 
access to HIV testing, which is a very important 
issue in our city.
Methods to diagnose TB are imperfect, therefore, 
many studies have shown that the association 
of fever, cough and weight loss should prompt 
diagnostic investigations in search for TB among 
HIV infected patients (15,16). In our study, confir-
mation of TB required the simultaneous use of 
multiple ZN stained smears and mycobacterial 
cultures, not only in pulmonary samples but also 
in many extrapulmonary specimens. In that sense, 
the study draws attention to the good diagnostic 
yield of the conventional methods such as ZN 
stain in all kind of samples (70% in respiratory 
samples and 51% in other samples), which could 
be explained by the multiple studies conducted in 
all affected organs (17-19). 
On the other hand, the systematic study of all 
bronchoalveolar lavage (BAL) samples with very 
well trained staff increases the diagnostic yield of 
pulmonary TB in HIV patients (17). Our findings 
are in keeping with previously published reports 
suggesting that traditional microbiologic tests are 
still effective to diagnose the TB/HIV co-infection 
(20-22), which highlights the importance of sample 
quality and their systematic study.
The rate of rifampicin resistance in our co-infected 
patients was more than three times the 1,5% ob-
served in the general population (23), similar to the 
5% estimated globally for MDRTB (24), but different 
to the 19% reported in Eastern Europe, 7% in the 
Western Pacific region (25), and up to 18-26% of 
newly diagnosed TB cases in some countries (26). 
According to these findings, testing for TB drugs 
susceptibility, especially with molecular methods 
for first- and second-line ones, are mandatory for 
the timely management of all co-infected patients. 
Resistance to rifampicin is usually associated with 
resistance to isoniazid and other drugs. However, 
monoresistance to rifampicin has been described 
in HIV-co-infected patients when they have been 
treated with intermittent rifampicin therapy and their 
CD4+ count is less than 100 cells/µL (27). It does 
not seem to be the problem in our patients, whose 
greatest risk of resistance is the poor adherence to 
the TB therapy (27-29); in fact, in the single patient 
whose resistance to rifampicin was confirmed only 
by Gene Xpert MTB, it was not possible to exclude 
resistance to other antibiotics.
Table 4. Risk factors associated with in-hospital mortality among co-infected HIV-TB patients (bivariate and multivariate analysis)
Variable Crude RR (95% CI) p value Adjusted RR (95% CI) p value
Prior antiretroviral therapy 0.80 (0.33-1.90) 0.61  
Homeless 1.02 (0.32-3.23) 0.98   
Prior TB 0.43 (0.10-1.76) 0.24 0.56 (0.15-2.01) 0.37
Hepatitis B infection 0.82 (0.21-3.13) 0.78 0.86 (0.22-3.38) 0.82
Pulmonary TB 1.66 (0.51-5.36) 0.40
Gastrointestinal TB 2.03 (0.86-4.81) 0.11 1.54 (0.70-3.38) 0.28
Meningeal TB 2.07 (0.76-5.62) 0.16
TB lymphadenitis 0.28 (0.08-0.91) 0.03 0.40 (0.12-1.36) 0.14
CD4 count <50/mL 5.17 (1.79-14.94) 0.00 3.94 (1.36-11.37) 0.01
Viral load ≥100,000 0.80 (0.35-1.83) 0.60
VDRL 1.58 (0.68-3.70) 0.29  
Hepatotoxicity 1.01 (0.36-2.83) 0.99  
Model adjusted by age
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Even though 50% of our patients experienced 
increases in ALT values after beginning the first-
line TB treatment, only 9.4% (15 out of 159) had 
to interrupt it because of liver toxicity; however, 
contrary to expectations, in our study high basal 
ALT values did not predict hepatotoxicity due to TB 
therapy and, therefore, it did not lead to changes 
in the treatment. This prevalence is similar to the 
rates reported in India by Saha, et al. (30), who 
identified co-infection with hepatitis B or hepatitis 
C as risk factors for liver toxicity. We measured 
ALT values before starting TB treatment and could 
follow them closely until patients were discharged. 
In this study, neither co-infection with hepatitis B or 
C were associated with hepatotoxicity due to TB 
drugs. As biomarkers to predict liver toxicity have 
not been developed yet, the findings highlight the 
importance of closely monitoring the ALT levels 
in all TB/HIV patients, and not only in those with 
chronic hepatic diseases.
As demonstrated in other studies, we found that 
CD4 counts below 50 cells/µL were associated 
with in-hospital mortality (31). Again, this underpins 
the need to address the factors underlying late 
access to therapy. This subgroup of patients should 
be closely monitored, and considering their high 
mortality risk and the non-significant relevance of 
the immune reconstitution inflammatory syndrome 
(IRIS) in most of them (only described in 4% of our 
patients), it is imperative to initiate the ART as soon 
as possible, usually two weeks after starting the TB 
treatment (32,33).
The main limitations of our study are related to its 
retrospective nature, and to the lack of a systematic 
database of co-infected patients in the city, which 
made it difficult to obtain results regarding the 
final outcome of TB treatment, patient survival or 
availability of antiretroviral drugs in the outpatient 
program. The date of death was not available either, 
so survival time could not be estimated. Bearing in 
mind that this study was conducted in a tertiary-
care hospital, it would be necessary to conduct 
additional studies in centers with different levels of 
complexity to better characterize the co-infection 
in our population and, of course, to identify the 
main challenges for their diagnosis and treatment. 
Given that approximately half of the patients was 
previously diagnosed with HIV and, yet, they 
advanced to severe immunosuppression, studying 
this group and identifying missed opportunities for 
linkage to care and antiretroviral therapy initiation 
is a public health imperative.
In conclusion, our study shows that even after 35 
years of HIV pandemic, TB is still a leading cause 
of advanced HIV diagnosis in our patients. The co-
infections affected young adults not aware of risky 
sexual behaviors who had limited access to HIV 
testing and presented with both extrapulmonary 
and pulmonary TB. As their resistance to rifampicin 
and/or MDRTB is around three times higher than 
in the general population, and patients frequently 
have to stop TB drugs because of liver toxicity 
(about 10%), which cannot be predicted by availa-
ble biomarkers, it is always necessary to monitor 
liver function closely during TB therapy and rule out 
drug resistance.
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